2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1371

Impact of Metabolic Syndrome (MetS) on Rheumatoid Arthritis Disease Activity
Abstract Number: 1062

Impact of Obesity on 1 Year Outcomes: Results from the Meteor Foundation International Rheumatoid Arthritis Cohort
Abstract Number: 824

Impact of Oral Glucocorticoid Therapy on Mortality in Patients with Rheumatoid Arthritis and Diabetic Mellitus
Abstract Number: 682

Impact of Patient’s Priorities on the Management of Systemic Lupus Erythematosus
Abstract Number: 2368

Impact of Physicians’ Adherence to Treat-to-Target Strategy on Outcomes in Early Rheumatoid Arthritis
Abstract Number: 2624

Impact of Provider Specialty on the Diagnosis and Management of Systemic Lupus Erythematosus in the American Indian/Alaska Native Population
Abstract Number: 1362

Impact of Rapid Attainment of Stringent Measures of Efficacy in Rheumatoid Arthritis on Patient-Reported Outcomes
Abstract Number: 2597

Impact of Repeating Imaging of the Sacro-Iliac Joints over One Year on the Classification According the ASAS Axial Spa Criteria of Patients
Abstract Number: 1069

Impact of Rheumatoid Arthritis on the Mortality of Patients Who Develop Cancer: A Population-Based Study
Abstract Number: 1522

Impact of Sarilumab on Health Related Quality of Life (HRQoL), Fatigue, and Sleep in Rheumatoid Arthritis Patients at Week 24 – Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study
Abstract Number: 709

Impact of Sleep Disorders in Quality of Life, Pain and Disease Activity Using Actigraphy and Pittsburgh Sleep Quality Index (PSQI)in Female with Systemic Lupus Ertyhematosus (SLE).
Abstract Number: 2618

Impact of Ustekinumab on Active Inflammation and Post-Inflammatory Structural Changes As Detected By Magnetic Resonance Imaging in Patients with Active Ankylosing Spondylitis: Results of a 28-Week, Prospective, Open-Label, Proof-of-Concept Study
Abstract Number: 29

Impaired Bone Healing in Patients Suffering from Rheumatoid Arthritis – Anti-Inflammatory Therapy As Confounder
Abstract Number: 2550

Impaired Speckle Tracking As a Marker of Subclinical Left Ventricular Dysfunction in Patients Affected By Primary Sjögren’s Syndrome
Abstract Number: 198

Implant Survival and Patient-Reported Outcomes after Total Hip Arthroplasty in Young Patients with JIA

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].